Repligen Corporation (RGEN)
Last Price$155.4(2.4%)
Market Cap$8,979.7M
RGEN Rating
RGEN Quality rating performance
RGEN Intrinsic Value
Key Highlights:
As of Mar 03, 2025 RGEN Relative Value is $60.4, which is overvalued by 61.1%, compared to current share price of $155.4.
As of Mar 03, 2025 RGEN DCF Value is $1.1, which is overvalued by 99.3%, compared to current share price of $155.4.
RGEN Share Price History
1W (5.7%)
1M (2.8%)
6M 9.6%
YTD (13.3%)
1Y (20.6%)
3Y (17.7%)
5Y 79.3%
10Y 523.8%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
RGEN Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$8,979.7M
$8,868.2M
$616.0M
$131.3M
Shares Outstanding
58M
Employees
N/A
Growth (CAGR)
19.5%
N/A
31.3%
140.74%
Profitability
46.9%
(0.8%)
(3.4%)
26.8%
21.3%
(633.3%)
Intrinsic Value
$29.8 (80.8% overvalued)
$1.1
$58.5
($23.3)
($5.1)
(6.8%)
Valuation (LTM)
Return on Capital
Financial Health
($111.5M)
(0.8x)
(0.3x)
33.3%
Dividends
Earnings
Apr 29, 2025
BEAT by 1.2%
BEAT by 22.0%
7 Beat & 3 Miss
RGEN Stock Financials
RGEN Income Statement Metrics
Annual
Quarterly
LTM
RGEN Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
$113.9M -33.8% YoY
Capital Expenditure (CAPEX)
($39.0M) -70.8% YoY
Free Cash Flow (FCF)
$74.9M +93.4% YoY
RGEN Income Statement Overview
Annual
Quarterly
LTM
Dec'14
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
$632.4M (21.1%) YoY
Cost of revenue
$323.5M (6.4%) YoY
Pre-tax income
$56.7M (74.1%) YoY
9.0% margin
RGEN Balance Sheet Overview
Annual
Quarterly
LTM
Dec'14
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Assets
Liabilities
Total assets
$2,831.2M
Current assets ($1,111.3M, 39.3% of total)
$751.3M (26.5%)
$124.2M (4.4%)
Other current assets
$235.9M (8.3%)
Non-current assets ($1,719.8M, 60.7% of total)
$6,471.0K (0.2%)
$323.0M (11.4%)
$400.5M (14.1%)
Other non-current assets
$989.9M (35.0%)
Financial position
($39.5M)
Cash & Short-term
Investments
Total Debt
RGEN Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
RGEN Earnings Surprises
Crunching data... Almost there!
RGEN Dividends
RGEN Dividend Yield
Crunching data... Almost there!
RGEN Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with RGEN
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$8,979.7M | 5.9 | $29.8 80.8% overvalued | (20.6%) | $616.0M | $131.3M | (8.0%) | 21.3% | 46.9% | (1.2%) | 33.3% | |
$207.3B | 6.9 | $106.1 81.3% overvalued | 41.5% | $8,352.1M | $1,077.2M | 17.2% | 12.9% | 67.5% | 26.8% | 0.0% | |
$66.3B | 6.1 | $262.7 15.0% undervalued | (1.4%) | $20.6B | $2,936.0M | 5.9% | 14.2% | 59.4% | 5.4% | 55.9% | |
$46.6B | 6.4 | $81.3 13.6% overvalued | 9.9% | $9,926.1M | $608.0M | 3.6% | 6.1% | 55.6% | 9.1% | 23.8% | |
$34.6B | 7.6 | $190.6 18.2% overvalued | 29.9% | $4,926.8M | $1,388.4M | 12.9% | 28.2% | 57.9% | 32.9% | 16.0% | |
$18.6B | 5.8 | $92.7 1.2% undervalued | (10.8%) | $3,895.4M | $288.1M | 8.4% | 7.4% | 62.8% | 5.9% | 32.0% | |
$17.9B | 4.7 | $52.7 51.1% undervalued | (16.2%) | $12.9B | $566.0M | (14.0%) | 4.4% | 37.1% | (1.5%) | 191.5% | |
$16.9B | 6.1 | $152.8 33.0% overvalued | (36.3%) | $2,893.1M | $276.4M | (1.9%) | 9.6% | 34.6% | 18.6% | 11.3% | |
$14.7B | 7.3 | $131.7 108.2% undervalued | (15.2%) | $4,038.9M | $1,135.5M | 1.8% | 28.1% | 56.2% | 13.2% | 1.0% | |
$10.4B | 5.2 | $139.9 26.6% overvalued | 50.3% | $2,094.4M | $145.3M | 2.3% | 6.9% | 48.0% | (14.8%) | 69.2% | |
$9,757.8M | 6.5 | $174.5 19.0% undervalued | 4.2% | $3,582.9M | $349.2M | 2.7% | 9.7% | 48.7% | 12.0% | 27.7% |
FAQ
What is Repligen Corporation (RGEN) stock rating?
As of today, Repligen Corporation has a stock rating of 6 (out of 10), which is considered Good.
is Repligen Corporation (RGEN) a good stock to buy?
As of today, Repligen Corporation has a Good stock rating, which is 80.8% overvalued. According to Value Sense backtesting, stocks with similar profile tend to underperform the market by 4.6%.